Delivery Order SPE2DB20D1051-SPE2DB24FD8LK

Award Date 6/26/24
Potential Completion Date 6/27/24
Potential Value $1.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,824.15, is for the provision of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of January 7, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,901.13, is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for the treatment of diabetes. The contract has an ultimate completion date of April 3, 2025. There is no set-aside designation, indicating this was an open competition. As a large...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,240.82, is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for the treatment of diabetes. The contract has an ultimate completion date of March 5, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA...
This is a $8,182.51 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of December 17, 2024 and was awarded on December 16, 2024. This contract is not associated with a set-aside designation,...
This is a $2,859.56 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an ultimate completion date of April 8, 2025 and is not designated as a set-aside contract. Amerisourcebergen holds a significant $999,999,999 Indefinite...
This is a $3,618.30 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication, to support military healthcare programs. The contract has an ultimate completion date of January 22, 2025 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $28,916.14, is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to treat diabetes. The contract has an ultimate completion date of May 24, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a $2,506.64 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to manage diabetes. The contract has an ultimate completion date of January 23, 2025 and is not designated as a set-aside. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,790.24, is for the provision of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of June 24, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for $10,778.70. The contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to treat diabetes. The contract has an ultimate completion date of November 8, 2024. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that has an Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA...
  • SPE2DB20D1051
    Indefinite Delivery Contract
  • SPE2DB20D1051-SPE2DB24FD8LK
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,098.72, is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for the treatment of diabetes. The contract has an ultimate completion date of June 27, 2024. Amerisourcebergen Drug Corp is the prime contractor, and the contract is not designated as a set-aside. The company maintains a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 5/17/25, 9:50 AM